Bevacizumab in Extensive Small Cell Lung Cancer (CPC)
Randomized Phase II-III Study of Bevacizumab 7,5 mg/kg in Combination With Chemotherapy Versus Chemotherapy in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy : PCDE (cisPlatin - Cyclophosphamide - epiDoxorubicin - Etoposide) or PE (cisPlatin - Etoposide)
Despite the fact that a substantial response rate may be obtained in small-cell lung cancers (using double-drug chemotherapy: cisplatin-etoposide, PE), a cure remains an exception. More aggressive regimens remain controversial and recent attempts at increasing dose-intensity have been restricted to patients with a more favourable presentation.
Bevacizumab is a humanized monoclonal antibody which binds to VEGF (Vascular Endothelial Growth Factor). In association with double-drug standard chemotherapies, it has been proven that bevacizumab can improve survival of previously untreated advanced non-small-cell lung cancers (NSCLC), compared to chemotherapy without bevacizumab). Such promising effects on NSCLC deserve to be tested on small-cell lung cancers.
In this trial (IFCT-0802), standard chemotherapy (PCDE or PE) will be compared to experimental treatment (PCDE or PE + bevacizumab 7.5 mg/kg) for previously untreated SCLC patients.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Ambilly, 프랑스, 74100
- Annemasse - CH
-
Angers, 프랑스, 49000
- Angers - CHU
-
Armentières, 프랑스
- Armentières - CH
-
Besancon, 프랑스, 25000
- CHU Besancon - Pneumologie
-
Caen, 프랑스, 14000
- Centre F. Baclesse
-
Caen, 프랑스, 14000
- CHU - Pneumologie
-
Cahors, 프랑스, 46000
- Cahors - CH
-
Chalons-en-Champagne, 프랑스
- Chalons-en-Champagne - CH
-
Chauny, 프랑스
- Chauny - CH
-
Clamart, 프랑스, 92140
- Hôpital Percy-Armées - Pneumologie
-
Clermont Ferrand, 프랑스, 63000
- Clermont Ferrand - CHU
-
Colmar, 프랑스, 68000
- Colmar - CH
-
Compiègne, 프랑스, 60300
- CH - Compiegne
-
Créteil, 프랑스, 94000
- Créteil - CHI
-
Dijon, 프랑스, 21000
- Dijon - CAC
-
Dijon, 프랑스, 63000
- Dijon - CHU
-
Draguignan, 프랑스, 83300
- Draguignan - CH
-
Grenoble, 프랑스, 38000
- CHU Grenoble - pneumologie
-
Harfleur, 프랑스, 76700
- Harfleur - Clinique du Petit Colmoulins
-
Helfaut, 프랑스, 62570
- Saint Omer - CHI
-
Jonzac, 프랑스, 17500
- Jonzac - CH
-
Le Coudray, 프랑스, 28630
- Chartres - CH
-
Le Mans, 프랑스, 72000
- Centre Hospitalier - Pneumologie
-
Longjumeau, 프랑스
- CH
-
Marseille, 프랑스, 13000
- APHM - Hôpital Sainte Marguerite
-
Marseille, 프랑스
- Marseille - CRLCC
-
Maubeuge, 프랑스, 59600
- Maubeuge - Polyclinique du Parc
-
Meaux, 프랑스, 77100
- Meaux - CH
-
Metz, 프랑스, 57000
- Metz - CHR
-
Mont de Marsan, 프랑스, 40000
- Mont de Marsan - CH
-
Montpellier, 프랑스, 34295
- Montpellier - CHRU
-
Mulhouse, 프랑스, 68000
- Mulhouse - CH
-
Neuilly, 프랑스, 92200
- Neuilly - Hôpital Américain de Paris
-
Nevers, 프랑스, 58033
- Nevers - CH
-
Nice, 프랑스, 06000
- Nice - CAC
-
Orléans, 프랑스, 45000
- Orléans - CH
-
Paris, 프랑스, 75012
- APHP - Saint-Antoine - pneumologie
-
Paris, 프랑스, 75020
- APHP - Hopital Tenon - Pneumologie
-
Pau, 프랑스, 64046
- Pau - CH
-
Pierre Bénite, 프랑스, 69495
- HCL - Lyon Sud (Pneumologie)
-
Reims, 프랑스, 51092
- Reims - CHU
-
Reims, 프랑스
- Reims - CRLCC
-
Rouen, 프랑스, 76000
- Rouen - CHU
-
Saint Brieuc, 프랑스, 22000
- Saint Brieuc - CHG
-
Saint Nazaire, 프랑스, 44600
- Saint Nazaire - Centre Etienne Dolet
-
Saint Priest en Jarez, 프랑스, 42270
- Saint Priest en Jarez - ICL
-
Saint Quentin, 프랑스, 02100
- Saint Quentin - CH
-
Saverne, 프랑스
- Saverne - CH
-
Senlis, 프랑스, 60300
- Senlis - CH
-
Strasbourg, 프랑스, 63000
- Nouvel Hopital Civil - Pneumologie
-
Suresnes, 프랑스, 92151
- Suresnes - Hopital Foch
-
Thonon les bains, 프랑스, 74200
- Thonon les bains
-
Toulon, 프랑스, 83000
- Toulon - HIA
-
Toulouse, 프랑스
- CHU Toulouse - Pneumologie
-
Toulouse, 프랑스
- Toulouse - Clinique Pasteur
-
Tours, 프랑스, 37000
- Tours - CHU
-
Vandoeuvre lès Nancy, 프랑스, 54500
- Nancy - CHU
-
Verdun, 프랑스
- Verdun - CHG
-
Vesoul, 프랑스, 70000
- Vesoul - CHI
-
Villejuif, 프랑스, 94800
- Institut Gustave Roussy
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria (must be checked at the inclusion, week -8):
- Small-Cell Lung Cancer histologically or cytologically proved
- Extended disease as defined by Veteran's Administration Lung Cancer Group (VALG)
- At least one unidimensionally measurable lesion (RECIST criterion)
- Age between 18 and 75 years
- Weight loss < 10% for the last three month
- Performance Status (PS)≤ 2
- Creatininemia < 110 µmol/L and creatinin clearance > 60 mL/min
- Neutrophils ≥ 1,500/µL and platelets ≥ 100,000/µL
- Bilirubin ≤ 1.5 x normal value
- Transaminases, Alkaline Phosphatase ≤ 2.5 x ULN excepted in case of liver metastasis (5xULN)
- Left ventricular ejection fraction (measured by echocardiographic or isotopic method) > 50% if PCDE is planned
- Electrocardiogram without uncontrolled coronaropathy
- Signed informed consent
Randomization Criteria (to be checked during the randomization (week 0)):
- Partial or complete tumoral response as defined by RECIST
- All chemotherapy-induced toxicities decreased to level ≤ 2 as defined by NCI CTC VS 3 (except for alopecia)
- Inclusion criteria concerning creatininemia, clearance, neutrophils, platelets, transaminases, alkaline phosphatases and left ventricular ejection fraction must be checked again
Exclusion Criteria:
- Non-Small-Cell Lung Cancer or mixed cancer (small-cell / non-small-cell)
- Previous antitumoral treatment of the small-cell lung cancer (chemotherapy, radiotherapy, immunotherapy, surgery)
- Non-extended disease as defined by VALG
- Natremia < 125 mmol/L
- Hypercalcemia whereas a corrective treatment
- Pathology contra-indicating the hyper-hydration
- Hemoptysis in the last three months
- Tumor invading large vessels or invading the proximal trachea-bronchial tree (visible at the medical imagery). Investigator or radiologist must reject tumors adjoining, merging or extending to large vessel's lumen (for example : pulmonary artery, superior vena cava)
- Symptomatic cerebral or meningeal metastasis
- Other cancer in progress or medical history of cancer in the five last years (excepted basal cell carcinoma or in situ cervical cancer of the uterus.
- Important surgical intervention (including surgical biopsy), traumatic lesion during 28 days before starting the treatment, or anticipation of an important surgical intervention during the study
- Minor surgical intervention, including implanting permanent catheter during the 24 hours before the first administration of bevacizumab
- Unhealed wound, evolutive gastroduodenal ulcer, fractured bone
- Medical history of abdominal fistula, trachea-oesophageal fistula, of another type with a severity rank of 4, gastrointestinal perforation or intraabdominal abscess during 6 month before inclusion
- Ongoing or recent use of aspirin (during 10 days before the first administration of bevacizumab) (>325 mg/day) or use of another platelet aggregation inhibitor (dipyridamole, ticlopidine, clopidogrel > 75 mg/day), or ongoing or recent use of a therapeutic dose (during 10 days before the first administration of bevacizumab) of anticoagulant or thrombolytic drugs per os or in parenteral injection. Prophylactic use of anticoagulant drug is allowed
- Medical history or genetic predisposition to bleeding or coagulopathy
- Clinically significative cardiac disease: infarct or CVA during 6 month before inclusion, unstable angina, congestive cardiac failure level > II as defined by New York Heart Association (NYHA) or cardiac arrythmia needing a specific treatment which risk to interfere with the study, or uncontrolled arrythmia.
- Known allergy or hypersensibility to monoclonal antibodies (bevacizumab), to chinese hamster ovary cells or to any humanized or recombinant antibody
- Uncontrolled high blood pressure (systolic pressure > 150 mm Hg and/or diastolic pressure > 100 mm Hg), with or without hypotension treatment. Patients presenting an high blood pressure are eligibles if their treatment can decrease their blood pressure to the values required by the protocol.
- Severe ongoing infectious disease or fever > 38.5°C or evidence of any other pathology, organic or neurologic functions deterioration, physical examination or laboratory result which cause suspicion of a disease which contra-indicate use of any studied treatment.
- Woman with a positive pregnancy test or who has not made a pregnancy test (unless pregnancy risk can be excluded)
- Lactating woman
- Sexually active woman who don't use hormonal or mechanical contraceptive method or sexually active man who has a sexually active partner who don't want to use an effective contraceptive method during the course of the study and during the 6 months after last treatment administration
- Patient who as already been included and treated in the present study
- Patient who participate or who has participated in another study during 4 weeks before treatment administration
- Patient who receive a previous antiangiogenic treatment (experimental or commercial : bevacizumab, thalidomide, CP-547632, sunitinib, sorafenib...)
- Geographical or psychological condition which not allowed a good comprehension or compliance to protocol
- Liberty deprived patient
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Arm A
4 additional cycles of chemotherapy
|
PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles |
|
실험적: Arm B
4 additional cycles of chemotherapy + bevacizumab
|
PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Response rate (complete response + partial response)
기간: 6 weeks after randomization
|
6 weeks after randomization
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Progression-free survival
기간: 12 weeks
|
12 weeks
|
|
Complete response length
기간: 12 weeks
|
12 weeks
|
|
삶의 질
기간: 12주
|
12주
|
|
Toxicities
기간: 12 weeks
|
12 weeks
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Jean-Louis PUJOL, Pr, CHRU Montpellier
간행물 및 유용한 링크
일반 간행물
- Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Geneve J, Maraninchi D. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol. 2007 Sep 1;25(25):3945-51. doi: 10.1200/JCO.2007.11.8109.
- Pujol JL, Daures JP, Riviere A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarie E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst. 2001 Feb 21;93(4):300-8. doi: 10.1093/jnci/93.4.300.
- Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009 Dec 10;27(35):6006-11. doi: 10.1200/JCO.2009.23.7545. Epub 2009 Oct 13.
- Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT). Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trialdagger. Ann Oncol. 2015 May;26(5):908-914. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.
- Negre E, Coffy A, Langlais A, Daures JP, Lavole A, Quoix E, Molinier O, Greillier L, Audigier-Valette C, Moro-Sibilot D, Westeel V, Morin F, Roch B, Pujol JL. Development and Validation of a Simplified Prognostic Score in SCLC. JTO Clin Res Rep. 2020 Feb 12;1(1):100016. doi: 10.1016/j.jtocrr.2020.100016. eCollection 2020 Mar.
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- IFCT-0802
- 2009-010187-42
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .